Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder

January 7, 2026 updated by: Intra-Cellular Therapies, Inc.

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment

This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo as adjunctive therapy to GAD treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD who have an inadequate response to ongoing GAD treatment.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The study will be conducted in 3 periods:

  • Screening Period (up to 3 weeks) during which patient eligibility will be assessed and the washout of prohibited medications will occur.
  • Double-blind Treatment Period (6 weeks) during which patients will be randomized in a 1:1:1 ratio to receive one of the 3 treatments (ITI-1284 10 mg, ITI-1284 20 mg, or placebo).
  • Safety Follow-up Period (1 week) during which all patients will return for a safety follow-up visit.

Study Type

Interventional

Enrollment (Estimated)

705

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Bulgaria
      • Blagoevgrad, Bulgaria, 2700
        • Recruiting
        • Clinical Site
      • Burgas, Bulgaria, 8001
        • Recruiting
        • Clinical Site
      • Pleven, Bulgaria, 5800
        • Recruiting
        • Clinical Site
      • Plovdiv, Bulgaria, 4002
        • Recruiting
        • Clinical Site
      • Rousse, Bulgaria, 7000
        • Recruiting
        • Clinical Site
      • Sofia, Bulgaria, 1113
        • Recruiting
        • Clinical Site
      • Sofia, Bulgaria, 1408
        • Recruiting
        • Clinical Site
      • Sofia, Bulgaria, 1680
        • Recruiting
        • Clinical Site
      • Sofia, Bulgaria, 1510
        • Recruiting
        • Clinical Site
      • Targovishte, Bulgaria, 7703
        • Recruiting
        • Clinical Site
      • Varna, Bulgaria, 9020
        • Recruiting
        • Clinical Site
      • Varna, Bulgaria, 9010
        • Recruiting
        • Clinical Site
      • Vratsa, Bulgaria, 3000
        • Recruiting
        • Clinical Site
  • Czechia
      • Brno, Czechia, 602 00
        • Recruiting
        • Clinical Site
      • Pilsen, Czechia, 301 00
        • Recruiting
        • Clinical Site
      • Prague, Czechia, 100 00
        • Recruiting
        • Clinical Site
      • Prague, Czechia, 160 00
        • Recruiting
        • Clinical Site
      • Prague, Czechia, 186 00
        • Recruiting
        • Clinical Site
  • Finland
      • Helsinki, Finland, 00100
        • Not yet recruiting
        • Clinical Site
      • Kuopio, Finland, 70110
        • Not yet recruiting
        • Clinical Site
      • Oulu, Finland, 90100
        • Not yet recruiting
        • Clinical Site
      • Tampere, Finland, 33210
        • Not yet recruiting
        • Clinical Site
  • Poland
      • Bialystok, Poland, 15404
        • Recruiting
        • Clinical Site
      • Bydgoszcz, Poland, 85-080
        • Recruiting
        • Clinical Site
      • Gorlice, Poland, 38300
        • Recruiting
        • Clinical Site
      • Leszno, Poland, 64100
        • Recruiting
        • Clinical Site
      • Poznan, Poland, 60744
        • Not yet recruiting
        • Clinical Site
      • Torun, Poland, 87100
        • Recruiting
        • Clinical Site
  • Serbia
      • Belgrade, Serbia, 11000
        • Recruiting
        • Clinical Site
      • Belgrade, Serbia, 11000
        • Recruiting
        • Clinical Site 2
      • Belgrade, Serbia, 11000
        • Recruiting
        • Clinical Site 3
      • Belgrade, Serbia, 11000
        • Recruiting
        • Clinical Site 4
      • Kovin, Serbia, 26220
        • Recruiting
        • Clinical Site
      • Kragujevac, Serbia, 34000
        • Recruiting
        • Clinical Site
      • Novi Kneževac, Serbia, 23330
        • Recruiting
        • Clinical Site
  • United States
    • Arizona
      • Chandler, Arizona, United States, 85224
        • Active, not recruiting
        • Clinical Site
    • California
      • Encino, California, United States, 91316
        • Recruiting
        • Clinical Site
      • Glendale, California, United States, 91206
        • Recruiting
        • Clinical Site
      • Imperial, California, United States, 92251
        • Recruiting
        • Clinical Site
      • Lemon Grove, California, United States, 91945
        • Recruiting
        • Clinical Site
      • Oceanside, California, United States, 92056
        • Recruiting
        • Clinical Site
      • Orange, California, United States, 92868
        • Recruiting
        • Clinical Site
      • Redlands, California, United States, 92374
        • Recruiting
        • Clinical Site
      • San Diego, California, United States, 92106
        • Active, not recruiting
        • Clinical Site
    • Connecticut
      • Farmington, Connecticut, United States, 06030
        • Recruiting
        • Clinical Site
    • Florida
      • Gainesville, Florida, United States, 32607
        • Withdrawn
        • Clinical Site
      • Lauderhill, Florida, United States, 33319
        • Recruiting
        • Clinical Site
      • Maitland, Florida, United States, 32751
        • Recruiting
        • Clinical Site
      • Miami, Florida, United States, 33122
        • Recruiting
        • Clinical Site
      • Miami, Florida, United States, 33125
        • Recruiting
        • Clinical Site
      • Miami, Florida, United States, 33176
        • Recruiting
        • Clinical Site
      • Miami Springs, Florida, United States, 33166
        • Recruiting
        • Clinical Site
      • Orlando, Florida, United States, 32803
        • Active, not recruiting
        • Clinical Site
      • Tampa, Florida, United States, 33634
        • Recruiting
        • Clinical Site
    • Georgia
      • Atlanta, Georgia, United States, 30331
        • Recruiting
        • Clinical Site
      • Decatur, Georgia, United States, 30030
        • Recruiting
        • Clinical Site
    • Massachusetts
      • Boston, Massachusetts, United States, 02131
        • Active, not recruiting
        • Clinical Site
    • Michigan
      • Ann Arbor, Michigan, United States, 48105
        • Recruiting
        • Clinical Site
    • New Jersey
      • Toms River, New Jersey, United States, 08755
        • Recruiting
        • Clinical Site
    • New York
      • Brooklyn, New York, United States, 11235
        • Recruiting
        • Clinical Site
    • Ohio
      • North Canton, Ohio, United States, 44720
        • Recruiting
        • Clinical Site
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73120
        • Recruiting
        • Clinical Site
    • Pennsylvania
      • Allentown, Pennsylvania, United States, 18104
        • Recruiting
        • Clinical Site
      • Media, Pennsylvania, United States, 19063
        • Recruiting
        • Clinical Site
    • Texas
      • Austin, Texas, United States, 78737
        • Recruiting
        • Clinical Site
      • Austin, Texas, United States, 78759
        • Recruiting
        • Clinical Site
      • DeSoto, Texas, United States, 75115
        • Active, not recruiting
        • Clinical Site
      • Plano, Texas, United States, 75093
        • Recruiting
        • Clinical Site
    • Washington
      • Bellevue, Washington, United States, 98007
        • Recruiting
        • Clinical Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Provide written informed consent before the initiation of any study specific procedures;
  2. Male or female patients ≥ 18 years of age;

  3. At Screening, meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) diagnostic criteria for moderate or severe GAD as confirmed by the Investigator or Sponsor-approved rater using the Structured Clinical Interview for DSM-5 Clinical Trials Version (SCID-5-CT), and meets all of the following at Screening and Baseline:

    1. HAM-A Total score of ≥ 22;
    2. HAM-A Items 1 (anxious mood) and 2 (tension) scores ≥ 2;
    3. CGI-S score of ≥ 4;
  4. History of inadequate response (< 50% improvement in anxiety symptoms as measured by the modified Antidepressant Treatment Response Questionnaire [ATRQ] for GAD) to at least 1 GAD-approved treatment (ie, one of the following GAD-approved treatments: paroxetine, venlafaxine XR, duloxetine, escitalopram, or buspirone) taken at an adequate dose (at least the minimum GAD-approved dose per package insert) and duration (ie, daily for at least 6 weeks) for the treatment of ongoing GAD symptoms;
  5. Currently having an inadequate response to one of the following GAD-approved treatments: paroxetine, venlafaxine XR, duloxetine, escitalopram, or buspirone taken at an adequate dose (at least the minimum GAD-approved dose per package insert) and duration (ie, for at least 6 weeks prior to Screening) and agrees to continue the same dosing regimen for the duration of the study.

NOTE: The current GAD-approved treatment must be different from the GAD treatment identified as the historical failure.

Exclusion Criteria:

  1. Within the patient's lifetime, has one of the following confirmed DSM-5-TR psychiatric diagnoses:

    1. Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or other psychotic disorder;
    2. Bipolar Disorder;
  2. MADRS total score > 18 at Screening or Baseline;

  3. In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during his/her participation in the study or

    1. At Screening, the patient scores "yes" on Suicidal Ideation Items 4 or 5 of the C-SSRS within 6 months prior to Screening or, at Baseline, the patient scores "yes" on Suicidal Ideation Items 4 or 5 since the Screening Visit;
    2. At Screening, the patient has had 1 or more suicidal attempts within the 2 years prior to Screening;
    3. At Screening or Baseline MADRS Item 10 score ≥ 5; or
    4. The patient is considered to be an imminent danger to him/herself or others based on the assessment of the Investigator.
  4. Lifetime history of failure to respond to > 3 of the approved treatments for GAD (ie, paroxetine, venlafaxine XR, duloxetine, escitalopram, or buspirone) at an adequate dose (ie, at least the minimum dose approved for GAD per package insert) and for an adequate duration (ie, at least 6 weeks).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
Drug: Placebo
Matching placebo tablet, taken once daily, sublingual administration
Experimental: ITI-1284 10mg
Drug: ITI-1284 10 mg
ITI-1284 10 mg tablet, taken once daily, sublingual administration.
Experimental: ITI-1284 20mg
Drug: ITI-1284 20 mg
ITI-1284 20 mg tablet, taken once daily, sublingual administration.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hamilton Anxiety Rating Scale (HAM-A)
Time Frame: Week 6
The HAM-A Scale is a clinician-rated scale measuring both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). It comprises of 14 items that are rated on a 5-point scale ranging from 0 = not present to 4 = very severe, disabling symptoms. The HAM-A total score ranges from 0 to 56 with a higher score indicating increased severity of anxiety symptoms.
Week 6

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical Global Impression Scale-Severity (CGI-S)
Time Frame: Week 6
The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients)
Week 6

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Intra-Cellular Therapies, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 5, 2024

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

June 1, 2027

Study Registration Dates

First Submitted

June 24, 2024

First Submitted That Met QC Criteria

June 24, 2024

First Posted (Actual)

June 28, 2024

Study Record Updates

Last Update Posted (Actual)

January 9, 2026

Last Update Submitted That Met QC Criteria

January 7, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ITI-1284-301

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Generalized Anxiety Disorder

Clinical Trials on ITI-1284 10 mg

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe